SAN DIEGO--(BUSINESS WIRE)--May 22, 2017--
Illumina, Inc. (NASDAQ: ILMN) announced today that Mark Van Oene has
been named Chief Commercial Officer. Van Oene was previously Illumina’s
Senior Vice President of the Americas region and subsequently named
interim Chief Commercial Officer in late 2016.
This Smart News Release features multimedia. View the full release here:
Illumina Chief Commercial Officer Mark Van Oene (Photo: Business Wire)
“Mark is a great leader for our commercial organization, possessing deep
genomics expertise and over a decade of experience building and running
strong sales and marketing teams,” said Francis deSouza, Illumina
President and Chief Executive Officer. “As interim Chief Commercial
Officer Mark has guided Illumina through two strong quarters, including
the launch of NovaSeq, and laid the foundation for our future growth. I
am excited to continue to work closely with Mark to expand our
commercial capability as we grow in research and clinical markets around
Van Oene joined Illumina in 2006 as Regional Account Manager for Canada.
In 2008, Van Oene was promoted to Senior Director of Sales for the
Americas. Four years later, he was promoted to Vice President with
responsibility for global sales. From 2012 through 2014, Van Oene led
the team to grow revenues from $1.06B to $1.42B. In early 2014, Van Oene
was named the General Manager for the Americas region, advancing to
Senior Vice President in April 2016. During that time, the Americas
compound annual growth rate exceeded 20%.
As Chief Commercial Officer, Van Oene will be responsible for world-wide
sales, services and marketing at Illumina. He will report to President
and CEO, Francis deSouza.
Van Oene earned a Bachelor of Science degree in Biochemistry from
Western University in London, Ontario, Canada.
Illumina is improving human health by unlocking the power of the genome.
Our focus on innovation has established us as the global leader in DNA
sequencing and array-based technologies, serving customers in the
research, clinical and applied markets. Our products are used for
applications in the life sciences, oncology, reproductive health,
agriculture, and other emerging segments. To learn more, visit www.illumina.com and
View source version on businesswire.com: http://www.businesswire.com/news/home/20170522005470/en/
Source: Illumina, Inc.